

# Young Chul Youn

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3708500/publications.pdf>

Version: 2024-02-01

127  
papers

2,125  
citations

257450

24  
h-index

289244

40  
g-index

157  
all docs

157  
docs citations

157  
times ranked

3350  
citing authors

#	ARTICLE	IF	CITATIONS
1	Prevalence, risk factors and consequences of cerebral small vessel diseases: data from three Asian countries. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2017, 88, 669-674.	1.9	151
2	The genetics of Alzheimer's disease. <i>Clinical Interventions in Aging</i> , 2014, 9, 535.	2.9	131
3	Oligomeric forms of amyloid- $\beta^2$ protein in plasma as a potential blood-based biomarker for Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2017, 9, 98.	6.2	108
4	Genetic analyses of early-onset Alzheimer's disease using next generation sequencing. <i>Scientific Reports</i> , 2019, 9, 8368.	3.3	91
5	Serum Vitamin D Status as a Predictor of Prognosis in Patients with Acute Ischemic Stroke. <i>Cerebrovascular Diseases</i> , 2015, 40, 73-80.	1.7	75
6	Clinical Characteristics of a Nationwide Hospital-based Registry of Mild-to-Moderate Alzheimer's Disease Patients in Korea: A CREDOS (Clinical Research Center for Dementia of South Korea) Study. <i>Journal of Korean Medical Science</i> , 2011, 26, 1219.	2.5	63
7	Artificial Neural Network: Understanding the Basic Concepts without Mathematics. <i>Dementia and Neurocognitive Disorders</i> , 2018, 17, 83.	1.4	62
8	Dynamic changes of oligomeric amyloid $\beta^2$ levels in plasma induced by spiked synthetic A $\beta^2$ 42. <i>Alzheimer's Research and Therapy</i> , 2017, 9, 86.	6.2	57
9	Characterization of mutations in <i>PRNP</i> (prion) gene and their possible roles in neurodegenerative diseases. <i>Neuropsychiatric Disease and Treatment</i> , 2018, Volume 14, 2067-2085.	2.2	56
10	Deep learning for EEG data analytics: A survey. <i>Concurrency Computation Practice and Experience</i> , 2020, 32, e5199.	2.2	50
11	Impact of White Matter Changes on Activities of Daily Living in Mild to Moderate Dementia. <i>European Neurology</i> , 2011, 65, 223-230.	1.4	45
12	Intracranial Internal Carotid Artery Calcification: A Representative for Cerebral Artery Calcification and Association with White Matter Hyperintensities. <i>Cerebrovascular Diseases</i> , 2010, 30, 65-71.	1.7	42
13	Effect of high-frequency repetitive transcranial magnetic stimulation on major depressive disorder in patients with Parkinson's disease. <i>Journal of Neurology</i> , 2016, 263, 1442-1448.	3.6	41
14	Coping with Dementia in the Middle of the COVID-19 Pandemic. <i>Journal of Korean Medical Science</i> , 2020, 35, e383.	2.5	40
15	APP, PSEN1, and PSEN2 Mutations in Asian Patients with Early-Onset Alzheimer Disease. <i>International Journal of Molecular Sciences</i> , 2019, 20, 4757.	4.1	38
16	Blood amyloid- $\beta^2$ oligomerization associated with neurodegeneration of Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2019, 11, 40.	6.2	38
17	Protective effect of boldine on dopamine-induced membrane permeability transition in brain mitochondria and viability loss in PC12 cells. <i>Biochemical Pharmacology</i> , 2002, 63, 495-505.	4.4	37
18	Prediction of cognitive impairment via deep learning trained with multi-center neuropsychological test data. <i>BMC Medical Informatics and Decision Making</i> , 2019, 19, 231.	3.0	37

#	ARTICLE	IF	CITATIONS
19	Blood Amyloid- $\beta^2$ Oligomerization as a Biomarker of Alzheimer's Disease: A Blinded Validation Study. <i>Journal of Alzheimer's Disease</i> , 2020, 75, 493-499.	2.6	35
20	Etiology of aseptic meningitis and clinical characteristics in immune-competent adults. <i>Journal of Medical Virology</i> , 2016, 88, 175-179.	5.0	34
21	Effects of Medial Temporal Atrophy and White Matter Hyperintensities on the Cognitive Functions in Patients with Alzheimer's Disease. <i>European Neurology</i> , 2011, 66, 75-82.	1.4	33
22	Depressive Symptoms are Associated with Progression to Dementia in Patients with Amyloid-Positive Mild Cognitive Impairment. <i>Journal of Alzheimer's Disease</i> , 2017, 58, 1255-1264.	2.6	31
23	Evaluation of coexistence of Alzheimer's disease in idiopathic normal pressure hydrocephalus using ELISA analyses for CSF biomarkers. <i>BMC Neurology</i> , 2014, 14, 66.	1.8	30
24	Clinical practice guideline for dementia by Clinical Research Center for Dementia of South Korea. <i>Journal of the Korean Medical Association</i> , 2011, 54, 861.	0.3	26
25	Genetic Factors of Cerebral Small Vessel Disease and Their Potential Clinical Outcome. <i>International Journal of Molecular Sciences</i> , 2019, 20, 4298.	4.1	25
26	Probable novel PSEN2 Val214Leu mutation in Alzheimer's disease supported by structural prediction. <i>BMC Neurology</i> , 2014, 14, 105.	1.8	24
27	Mutations, associated with early-onset Alzheimer's disease, discovered in Asian countries. <i>Clinical Interventions in Aging</i> , 2016, Volume 11, 1467-1488.	2.9	24
28	Self- and informant-reported cognitive functioning and awareness in subjective cognitive decline, mild cognitive impairment, and very mild Alzheimer disease. <i>International Journal of Geriatric Psychiatry</i> , 2020, 35, 91-98.	2.7	24
29	Brachial-ankle pulse wave velocity is associated with both acute and chronic cerebral small vessel disease. <i>Atherosclerosis</i> , 2016, 245, 54-59.	0.8	23
30	Use of the Clock Drawing Test and the Rey-Osterrieth Complex Figure Test-copy with convolutional neural networks to predict cognitive impairment. <i>Alzheimer's Research and Therapy</i> , 2021, 13, 85.	6.2	23
31	Voxel-based morphometric study of brain volume changes in patients with Alzheimer's disease assessed according to the Clinical Dementia Rating score. <i>Journal of Clinical Neuroscience</i> , 2011, 18, 916-921.	1.5	22
32	Rivastigmine patch reduces the incidence of postoperative delirium in older patients with cognitive impairment. <i>International Journal of Geriatric Psychiatry</i> , 2017, 32, 1079-1084.	2.7	21
33	Clinical and Neuropsychological Comparisons of Early-Onset Versus Late-Onset Frontotemporal Dementia: A CREDOS-FTD Study. <i>Journal of Alzheimer's Disease</i> , 2015, 45, 599-608.	2.6	19
34	A Comprehensive Visual Rating Scale of Brain Magnetic Resonance Imaging: Application in Elderly Subjects with Alzheimer's Disease, Mild Cognitive Impairment, and Normal Cognition. <i>Journal of Alzheimer's Disease</i> , 2015, 44, 1023-1034.	2.6	19
35	A voxel-based morphometric study of cortical gray matter volume changes in Alzheimer's disease with white matter hyperintensities. <i>Journal of Clinical Neuroscience</i> , 2012, 19, 1506-1510.	1.5	18
36	Detection of cognitive impairment using a machine-learning algorithm. <i>Neuropsychiatric Disease and Treatment</i> , 2018, Volume 14, 2939-2945.	2.2	18

#	ARTICLE	IF	CITATIONS
37	Clinical utility of serum hepcidin and iron profile measurements in Alzheimer's disease. <i>Journal of the Neurological Sciences</i> , 2019, 403, 85-91.	0.6	18
38	Effect of White Matter Hyperintensity on Medial Temporal Lobe Atrophy in Alzheimer's Disease. <i>European Neurology</i> , 2013, 69, 229-235.	1.4	17
39	Analysis of Cerebrospinal Fluid and [11C]PIB PET Biomarkers for Alzheimer's Disease with Updated Protocols. <i>Journal of Alzheimer's Disease</i> , 2016, 52, 1403-1413.	2.6	17
40	Glycyrrhizin Prevents 7-Ketocholesterol Toxicity Against Differentiated PC12 Cells by Suppressing Mitochondrial Membrane Permeability Change. <i>Neurochemical Research</i> , 2009, 34, 1433-1442.	3.3	16
41	Novel PSEN1 p.Gly417Ala mutation in a Korean patient with early-onset Alzheimer's disease with parkinsonism. <i>Neurobiology of Aging</i> , 2018, 72, 188.e13-188.e17.	3.1	16
42	A Comparative Evaluation of the KDSQ-C, AD8, and SMCQ as a Cognitive Screening Test to Be Used in National Medical Check-ups in Korea. <i>Journal of Korean Medical Science</i> , 2019, 34, e111.	2.5	16
43	A Consensus in Korea Regarding a Protocol to Reduce Preanalytical Sources of Variability in the Measurement of the Cerebrospinal Fluid Biomarkers of Alzheimer's Disease. <i>Journal of Clinical</i>		

#	ARTICLE	IF	CITATIONS
55	Neuropsychological Correlates of the Proportional Impact of White Matter Hyperintensities on Mild to Moderate Dementia: The MRI 300 Study. <i>Dementia and Geriatric Cognitive Disorders</i> , 2011, 31, 397-405.	1.5	11
56	Posterior atrophy predicts time to dementia in patients with amyloid-positive mild cognitive impairment. <i>Alzheimer's Research and Therapy</i> , 2017, 9, 99.	6.2	11
57	Cerebrospinal Fluid Levels of $\hat{\text{I}}^2$ -Amyloid 40 and $\hat{\text{I}}^2$ -Amyloid 42 are Proportionately Decreased in Amyloid Positron-Emission Tomography Negative Idiopathic Normal-Pressure Hydrocephalus Patients. <i>Journal</i>		



#	ARTICLE	IF	CITATIONS
73	Neuroleptic malignant syndrome induced by phenytoin in a patient with drug-induced Parkinsonism. <i>Neurological Sciences</i> , 2014, 35, 1641-1643.	1.9	6
74	Age-Specific Cutoff Scores on a T1-Weighted Axial Medial Temporal-Lobe Atrophy Visual Rating Scale in Alzheimer's Disease Using Clinical Research Center for Dementia of South Korea Data. <i>Journal of</i>		



#	ARTICLE	IF	CITATIONS
91	Machine learning based EEG biomarker for early screening of amnesic mild cognitive impairment (aMCI). Alzheimer's and Dementia, 2020, 16, e044381.	0.8	2
92	Dynamic association between AT(N) profile and cognition mediated by cortical thickness in Alzheimer's continuum. NeuroImage: Clinical, 2020, 27, 102282.	2.7	2
93	A Voxel Based Morphometric Analysis of Longitudinal Cortical Gray Matter Changes in Progranulin Mutation Carriers At-Risk for Frontotemporal Dementia: Preliminary Study. Dementia and Neurocognitive Disorders, 2015, 14, 163.	1.4	2
94	Steroid responsive rhombencephalitis and optic neuritis with autoimmune thyroid disease. Neurological Sciences, 2015, 36, 813-815.	1.9	1
95	P2-092: Novel, PSEN1 T119I Mutation in an Early-Onset Alzheimer's Disease Patient. Alzheimer's and Dementia, 2016, 12, P645.	0.8	1
96	Depressive Symptoms and Cognitive Improvement in Patients with Dementia with Lewy Bodies. Journal of Alzheimer's Disease, 2019, 71, 899-905.	2.6	1
97	Cerebellar distortion after a cystoperitoneal shunt for arachnoid cyst. Neurology India, 2011, 59, 467.	0.4	1
98	A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase IIb Clinical Study to Evaluate the Safety and Efficacy of DHP1401 in Patients with Mild to Moderate Alzheimer's Disease Treated with Donepezil: DHP1401 Randomized Trial in Mild to Moderate Alzheimer's Disease (DRAMA). Journal of Alzheimer's Disease, 2022, 87, 391-403.	2.6	1
99	P3-228: A COMPREHENSIVE VISUAL RATING SCALE ON BRAIN MRI: APPLICATION TO ALZHEIMER'S DISEASE, MILD COGNITIVE IMPAIRMENT, AND SUBJECTIVE MEMORY IMPAIRMENT. , 2014, 10, P714-P714.		0
100	P1-132: PATHOGENIC PSEN1 MUTATION DETECTED IN A KOREAN EOAD PATIENT. , 2014, 10, P348-P348.		0
101	IC-P-035: CORRELATION BETWEEN CSF BIOMARKERS AND QUANTIFIED PIB BURDEN IN ALZHEIMER'S DISEASE PATIENTS. , 2014, 10, P21-P22.		0
102	P3-015: Novel PSEN1 mutation (E280K) in a malaysian family. , 2015, 11, P625-P625.		0
103	P4-217: Novel A $\beta$ 2 specific recombinant monoclonal antibodies with high sensitivity. , 2015, 11, P863-P863.		0
104	P2-018: Novel, probably pathogenic PSEN1 mutation (G209A) in a korean Alzheimer's disease patient. , 2015, 11, P488-P488.		0
105	P1-056: Genetics of early-onset Alzheimer's disease (AD) in korea: An update. , 2015, 11, P359-P360.		0
106	P1-057: Novel, probably pathogenic PSEN1 mutation (L232P) in a korean Alzheimer's disease patient. , 2015, 11, P360-P360.		0
107	P3-102: Genetic Screening for TAU (MAPT) Mutations in Korean Early Onset Alzheimer's Disease Patients. Alzheimer's and Dementia, 2016, 12, P858.	0.8	0
108	P1-125: A Possible Pathogenic Psen2 Mutation, H169N in a Korean Eoad Patient. Alzheimer's and Dementia, 2016, 12, P451.	0.8	0

#	ARTICLE	IF	CITATIONS
109	P4-050: Two Novel GRN Mutations in Korean Patients Diagnosed with Early Onset Alzheimer's Disease. , 2016, 12, P1033-P1033.		0
110	[P3-250]: AMYLOID BETA OLIGOMERIZATION IN PLASMA AS A POTENTIAL BLOOD-BASED BIOMARKER FOR ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2017, 13, P1038.	0.8	0
111	[P4-068]: THREE NOVEL PATHOGENIC VARIANTS IN CLUSTERIN (CLU) ASSOCIATED WITH EARLY-ONSET ALZHEIMER DISEASE. Alzheimer's and Dementia, 2017, 13, P1283.	0.8	0
112	[P3-086]: NOVEL AND KNOWN RARE SORL1 MUTATIONS IN KOREAN AD PATIENTS. Alzheimer's and Dementia, 2017, 13, P965.	0.8	0
113	[P3-113]: MUTATIONAL ANALYSIS OF PRNP IN EARLY ONSET ALZHEIMER'S DISEASE IN KOREA. Alzheimer's and Dementia, 2017, 13, P977.	0.8	0
114	[P1-162]: GENETIC ANALYSES OF YOUNG PATIENTS WITH ALZHEIMER'S DISEASE FROM NEXT GENERATION SEQUENCING. Alzheimer's and Dementia, 2017, 13, P305.	0.8	0
115	[P2-127]: HIGH FREQUENCY OF ABCA7 MUTATIONS IN PATIENTS WITH EARLY-ONSET ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2017, 13, P655.	0.8	0
116	P1-257: A BLOOD TEST OF AMYLOIDOPATHY FOR DIAGNOSIS OF ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2018, 14, P379.	0.8	0
117	P1-033: A MULTICENTER, RANDOMIZED, OPEN-LABEL, PROSPECTIVE TRIAL TO EVALUATE THE SAFETY OF DONEPEZIL HYDROCHLORIDE 23 MG WITH OR WITHOUT INTERMEDIATE DOSE TITRATION IN PATIENTS WITH ALZHEIMER'S DISEASE TAKING DONEPEZIL HYDROCHLORIDE 10 MG: ODESA STUDY. Alzheimer's and Dementia, 2018, 14, P279.	0.8	0
118	P4-561: DEPRESSIVE MOOD AND COGNITIVE INSTABILITY IN PATIENTS WITH DEMENTIA WITH LEWY BODIES. Alzheimer's and Dementia, 2019, 15, P1534.	0.8	0
119	Differences in quantitative electroencephalogram and voxel-based volumetry between encoding and retrieval in amnesic mild cognitive impairment. Alzheimer's and Dementia, 2020, 16, e044426.	0.8	0
120	Effects of Body Weight on the Safety of High-Dose Donepezil in Alzheimer's Disease: Post hoc Analysis of a Multicenter, Randomized, Open-Label, Parallel Design, Three-Arm Clinical Trial. Dementia and Geriatric Cognitive Disorders, 2021, 50, 289-295.	1.5	0
121	Efficacy of the Phosphorylated tau 181 in Differential Diagnosis of the Alzheimer's Disease: A Systematic Review and Meta-Analysis. Dementia and Neurocognitive Disorders, 2014, 13, 129.	1.4	0
122	Neuroprotective effects of tumor necrosis factor- $\alpha$ inhibitor on rat hippocampal organotypic slice cultures treated with the 1-42 $\beta$ -amyloid. , 0, , .		0
123	CSF total tau/ $\beta$ -synuclein ratio improved the diagnostic performance for Alzheimer's disease as an indicator of tau phosphorylation. Alzheimer's and Dementia, 2021, 17, .	0.8	0
124	Digital Trail Making Test-Black & White: Normal vs MCI. Alzheimer's and Dementia, 2021, 17, .	0.8	0
125	Comparison of RCF scoring system to clinical decision for the Rey complex figure using machine-learning algorithm. Alzheimer's and Dementia, 2021, 17, .	0.8	0
126	Survival in Korean Patients with Frontotemporal Dementia Syndrome: Association with Behavioral Features and Parkinsonism. Journal of Clinical Medicine, 2022, 11, 2260.	2.4	0



#	ARTICLE	IF	CITATIONS
127	Neuropsychological test using machine learning for cognitive impairment screening. Applied Neuropsychology Adult, 0, , 1-6.	1.2	0